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Cover Art: Roni Hetzel, Meds 2018
Description: The cover art is a
portrait of Blackie (Herman Lee)
Wall, grandfather of Roni Hetzel,
Meds 2018. This work captures the
phenomenon of aging, demonstrating that although the physical body
transforms, the elderly man has the
same unique and defining human
spirit as his younger self. This idea
shapes the way we interact with our
aging patient population, as we treat
our patients with revered dignity
that appreciates their personhood,
past but also equally present.
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editorial

Medicine’s eternal struggle
The pursuit of human health is, in many
ways, a never-ending battle. Winning one fight,
curing one disease, or successfully managing one
condition simply buys time for the next concern
to arise. It is sometimes commented that the conditions that consume most of our time, attention,
and resources in health care are the direct result
of prior successes in medicine. One hundred
and fifteen years ago, infections were the leading cause of death. As we improved our ability
to combat these maladies, heart disease became
our primary reason for leaving this world behind,
followed closely by malignant neoplasms. The
additional years of life gained when large swaths
of the population no longer fell victim to influenza, tuberculosis, or the latest stomach bug gave
more time for our coronary arteries to narrow or
for malignant cells to grow and multiply within
our bodies.1
This diatribe may sound defeatist, but within the cold reality that medicine will never truly conquer death lies a rather comforting truth:
medicine has become quite effective at denying
our ultimate mortality for a significant period of
time. Each medical discovery may only delay the
inevitable, but the time bought can amount to decades. Indeed, though medical advances can only
take credit for a portion of this change, life expectancy since 1900 has increased by approximately
30 years in North America.2
The emergence and expansion of geriatric
medicine in many ways represents the clearest
demonstration of the triumph of modern health
care. With many more individuals living so long

we now need a whole field of medicine, with dedicated practitioners, to manage the unique challenges of growing old and remaining as healthy
as possible at an advanced age.
It is difficult to overemphasize the importance of geriatric medicine at this juncture in
history. The wave of baby boomers has begun
the transition to retirement and the start of their
senior years.3 Our health care system is in the
midst of tackling tough questions on cost and
sustainability, exploring new models of care and
compensation, all with care for the elderly as a
central concern.4 The recent Supreme Court of
Canada decision on physician-assisted death has
brought forth a new national conversation on the
role of dying in medicine and society at large, a
conversation with particular relevance for the
elderly.5
It is in this context that the UWOMJ presents our issue on geriatric medicine. Challenges
abound in the field of geriatrics. As we meet these
challenges and, with luck, prove equal to them,
new issues will arise to take their place. Yet, just
as the problems posed in geriatric medicine today
are the result of the successes of the past, so too
will the problems of the future demonstrate the
accomplishments of the present. We hope this issue provides a taste of both the unique challenges
within geriatric medicine, as well as the potential
solutions moving forward, contributing to an ever-brighter path to old age.
Craig Olmstead
Junior Associate Editor
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Multimorbidity in family medicine clerkship
The student perspective

Emily Harrison (Meds 2015)
Faculty Reviewers: Dr William E Osmun, MD, CCFP (Department of Family Medicine), Dr George Kim, MD, CCFP (Department of
Family Medicine)

abstract
PURPOSE: To document senior medical students’ experiences in caring for patients with multiple chronic illnesses in
family medicine clerkship and explore their attitudes towards
the inclusion of this topic in existing curricula.
METHODS: A cohort of third-year medical students from
the Schulich School of Medicine and Dentistry at the University
of Western Ontario were surveyed following their core family
medicine clerkship.
RESULTS: One hundred percent of students surveyed participated in the care of patients with multiple chronic illnesses during their family medicine clerkship. However, only 28%
percent reported receiving formal teaching on this topic while
89.5% felt that multimorbidity should be taught at the clerkship
level. The majority of students surveyed felt comfortable caring
for this patient population.
CONCLUSION: Patients with multiple chronic illnesses
are common in family practice. All third-year medical students
encountered patients with multimorbidity during their family
medicine clerkship. This study contributes to a growing body
of literature that suggests the need for a shift in medical education and health care delivery in order to better serve an increasingly complex patient population.

on a single-disease model and provide little guidance for the management of multiple chronic illnesses within one patient.3,6,9,10 Our
previous work has shown that medical undergraduate educators
agree that clinical clerks should be exposed to the management of
multiple chronic illnesses in family medicine training; however, the
majority of existing curricula do not address this topic.11
The purpose of this study was to document medical students’
experiences caring for patients with multiple morbidities and explore their perspectives on the teaching of multimorbidity in family
medicine clerkship.

methods
A 12-item, paper-based survey was developed aimed at documenting students’ experiences caring for patients with multiple
chronic illnesses during their core family medicine rotation. Primary survey items explored students’ attitudes towards receiving formal teaching on patients with multiple morbidities at the
clerkship level. Participants were given the opportunity to provide
further comments on their experiences caring for patients with
multiple chronic illnesses as well as feedback on the survey in an
open-ended question. Formal teaching was defined as structured
learning that takes place in the following formats: lectures, resident
Table 1: Format of multimorbidity teaching in family medicine clerkship,
choose all that apply (n = 13)

introduction
Canadian medical undergraduate trainees enter clerkship in
either their second or third year and for many this is their first exposure to clinical practice. Primary care educators are challenged
with introducing medical students to the broad range of topics
present in family medicine.1 The Canadian Undergraduate Family
Medicine Education Directors have published the Canadian Shared
Family Medicine Clerkship Curriculum in an effort to provide
learners with resources to supplement their clerkship experiences.2 This learning tool provides objectives, reference cards and cases for 23 common presentations in family practice. However, there
is no information relating to the management of patients with multiple chronic illnesses. Multimorbidity is defined as the presence
of two or more chronic medical conditions within one individual.3
The prevalence of such patients is increasing, and family physicians
play an important role in their medical care.3-8 Numerous studies
have shown that patients with multiple morbidities experience a
decreased quality of life, worse health care outcomes and lower level of functional status.4-8 It is important that medical trainees are
appropriately trained to care for an increasingly complex patient
population. Medical education and treatment guidelines are based
UWOMJ 84:2 | Fall 2015

Answer options

Response percent Response count

Lectures/rounds

38.5%

5

Topic presentations

15.4%

2

Small-group discussions

30.8%

4

Assigned readings

30.8%

4

Online case modules

0.0%

0

OSCE

0.0%

0

Resident teaching

76.9%

10

Other (please specify)

38.5%

5

Table 2: Do you feel that you have a practical approach to the management of
patients with multiple morbidities in family practice? (n = 56)
Answer options
Yes

Response percent Response count
55.4%

31

No

17.9%

10

Unsure

26.8%

15
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Table 3: On a scale of 1-10, how comfortable are you with the management of patients with multiple chronic illnesses? (n = 57)
Answer options

1

2

3

4

5

6

7

8

9

10

Rating average Standard deviation

Response Count

0

0

1

2

10

10

21

9

4

0

6.60

Table 4: Do you think that third year clinical clerks should be taught an
approach to the management of patients with multiple morbidities during the
family medicine rotation? (n = 57)
Answer options

Response percent Response count

Yes

89.5%

51

No

1.8%

1

Unsure

8.8%

5

Table 5: If you have any further comments regarding multimorbidity in your
family medicine rotation, please include them below (n = 6)
It’s difficult to have an approach to multiple morbidities early on and I think
it is something that comes with more clinical experience.
Seems very vague; not every patient will be the same. How extensive is the
teaching going to be? Not sure if it’s necessary.
Geriatrics during internal was the only place we really saw multimorbidity
discussed - it was great, but a bit more would be nice.
IM had formal teaching in multimorbidity in the context of geriatrics.
Multimorbidity is the rule in family. We didn’t learn a pocket approach.
Haven’t done surgery yet so can’t comment.

teaching, online modules and assigned readings. Students received
surveys following the final assessment of their core family medicine rotation and completed surveys were entered into an electronic database for analysis. Third-year medical students who had
completed their family medicine rotation at the Schulich School of
Medicine and Dentistry between April 2014 and September 2014
were eligible to participate. Ethics approval was obtained from the
University of Western Ontario’s Research and Ethics Board.

results
Paper surveys were distributed to a total of 63 students and
57 were returned, giving a response rate of 90%. All participants
were part of the 2015 class at Western University. Of these, 81% of
respondents completed their family medicine clerkship in a rural
setting, while 100% of respondents indicated that multimorbidity was common in family practice and 100% were involved in the
care of patients with multiple chronic illnesses during their family
medicine clerkship. However, only 28.1% received formal teaching
on the management of such patients. Those who did receive formal
teaching were asked to list the formats utilized by their preceptors
during the core family medicine rotation (Table 1). However, of
those who did not receive formal teaching on multimorbidity, 81%
indicated that their preceptors discussed the management of patients with multiple chronic illnesses. Respondents were asked to
indicate if they felt they had a practical approach to patients with
multiple chronic illnesses (Table 2). Respondents were also asked
to indicate on a 10-point Likert scale whether they felt comfortable caring for patients with multiple morbidities, 10 indicating a
high level of comfort and 1 indicating a low level of comfort (Table
UWOMJ 84:2 | Fall 2015

1.30

3). The average response was 6.60 (SD = 1.30). Respondents were
asked to indicate whether multimorbidity should be included in
formal teaching during the family medicine rotation (Table 4) and
if they had received formal teaching on this topic in any other core
rotation during their clerkship training. Internal medicine was the
most common (48/50), followed by psychiatry (17/50) and surgery
(10/50). Respondents were given the opportunity to provide any
further comments about their experiences with multimorbidity in
family medicine clerkship (Table 5).

discussion
All students surveyed were involved in the care of patients with
multiple chronic illnesses during their family medicine rotation
and the vast majority felt that third-year clinical clerks could benefit from formal teaching on multimorbidity. These findings further
support the literature indicating that patients with multiple chronic illnesses are increasingly common in family practice and that
medical education fails to address the needs of this patient population.3-8,10-11 Respondents indicated that they received formal teaching on multimorbidity in other clinical areas, internal medicine
(48/50) being the most common. Interestingly, more than half of
respondents indicated that they felt comfortable caring for patients
with multiple chronic illnesses in a primary care setting, despite the
paucity of formal teaching on this topic within the family medicine
curriculum. It was surprising that the majority of students surveyed
indicated a relatively high level of comfort in caring for such a complex patient population. However, literature on undergraduate education suggests medical students’ ability to accurately assess their
own performance and knowledge base is highly variable and often
inaccurate.12-14 Future studies could focus on senior medical students’ ability to self-assess their proficiency in caring for patients
with multimorbidity.
The responses to the open-ended survey item, while few in
number, suggest the need for further study on students’ experiences caring for patients with multiple chronic illnesses. Focus groups
with senior medical students could provide a more complete view
of their experiences in family medicine clerkship and could be useful in the development of learning tools to aid in the care of patients
with multimorbidity.
This study is not without limitations; our survey instrument
was not previously validated, and respondents commented during
the survey session that some items were unclear. We surveyed a
cohort of third-year students exclusively from Western University
and therefore our findings may not be representative of the experience of undergraduate trainees at other institutions.
Despite these limitations, this study speaks to the need for further development in family medicine undergraduate education beyond the single-disease model.

acknowledgments
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Advanced care planning

A patient-centered approach to end-of-life care
Konstantinos Alexopoulos (Meds 2016)
Faculty Reviewer: Dr Ravi Taneja, MD, FRCPC (Departments of Anesthesiology and Critical Care)

introduction
The scenario is all too familiar to the critical care physician
working in a major teaching centre, or perhaps, even a peripheral
intensive care unit (ICU) with limited capacity: an elderly patient
is admitted to the emergency department status post-acute stroke.
The patient has developed a high systolic blood pressure, a widened pulse pressure and abnormal respirations, which all point to
increased intracranial pressure and a potential risk for brain stem
herniation. A plan is made to admit the patient to the ICU for definitive management, which includes endotracheal intubation, ventilatory support, a hypnotic infusion and an osmotic diuretic like
mannitol.1 The following morning, the patient’s family arrives and
there are medical decisions to be agreed upon and executed through
a family meeting. Up until this point in this patient’s life, there has
been no formal discussion between family members around the
topic of end-of-life care.2 No substitute decision maker (SDM) has
been appointed. This culminates in family members vehemently
disagreeing on what their loved one would have wanted. The critical care specialist physician is in a moral quandary. Like most things
in medicine, effective advanced care planning is a prerequisite for
success. However, there are always barriers to overcome in the process of planning, especially when it comes to death and dying.
Advance care planning (ACP) results in an advanced directive
that expresses one’s future preferences for medical decisions when
one might be incapable of making such decisions.3 The goal of ACP
is to improve patient-centred care and potentially reduce the intensification of care at the end of life.4 The ACP process is a topdown modus operandi. The big picture involves making the transition from living to dying as painless as possible from every facet:
medical, physical, emotional, spiritual and religious. Unfortunately,
these psychosocial needs tend to be forgotten in the early stages of
managing a patient in critical condition. From a medical perspective, the ICU was developed in the mid-20th century to facilitate
invasive monitoring and medical intervention to those critically ill
or injured patients. Critical care medicine burgeoned into a mecca
of technological and life-saving advancements.5 As a direct consequence of the development of the ICU, some physicians have proposed that Western society has overmedicalized the experience of
death and dying. Rather than dying at home surrounded by friends
and family, the elderly have been wasting away and dying in a sterile
hospital setting.6 The idea of extending life without consideration
for quality of life has been a topic of contention in the management
and allocation of ICU-specific resources. Canadian physicians are
having to come up against the harsh reality that these resources are
limited. Being cognizant of this, physicians need to overcome their

UWOMJ 84:2 | Fall 2015

inherent paternalistic instinct to keep a patient alive using invasive
monitoring, vasopressors and mechanical ventilation. Failure to
identify the point where medical intervention can unintentionally
prolong patient suffering is a disservice to the patients and their
families.

discussion
Patients who are terminally ill consistently identify their top
priorities as avoiding suffering, being with family and not becoming
a burden to others, but SDMs often do not realize this.2 An example to illustrate this would be a patient with heart failure and underlying arrhythmia that resulted in the placement of an internal
defibrillator/pacemaker. The patient’s condition has deteriorated
and the patient is admitted to hospital for medical management.
Over the last few days of the patient’s life, the family watches their
loved one progress through the stages of dying. Intermittently, the
defibrillator fires, causing discomfort to patient and family alike.
Despite this, the patient’s husband as her SDM refuses to deactivate the defibrillator because he does not want to be responsible for
killing her. Herein arises the issue of education surrounding endof-life care and decision making facilitated by an open dialogue between all parties involved.
ACP at its core is meant to be a process that facilitates communication and engages the participant in ongoing reflection.4 Ideally, ACP involves members of the healthcare team, family members
and loved ones. A large barrier to the process is the unwillingness
of some patients to engage in these discussions, because they are
forced to face the gravity of their illness and prognosis. Conversely, physicians often avoid the topic because their paternalistic instinct hopes to shield the patients from the harsh reality of their
mortality. While there is a certain degree of emotional upset that
is bound to occur, most patients when offered a chance to discuss
their wishes have found such conversations empowering.7,8 In modern medical practice, a patient-centred approach is emphasized and
valued highly. However, it may be inappropriate to initiate ACP discussions at the onset of terminal illness. In doing so, we may be indeed asking the patient to predict the individual course of his or her
disease process. This violates a core tenet of patient-centred care:
that pathology is not experienced on a universal level by all. Rather,
illness is defined as a unique experience within a biopsychosocial
model that includes not only scientific fact, but humanistic factors
like emotional and cultural differences.
Recent research at the Schlegel Institute for Aging at the University of Waterloo has provided some valuable insight to assist in
guiding the patient experience in preparing for death and dying.
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Less than half of those Canadians interviewed had discussed their
preferences for end-of-life care with someone. An overwhelming
majority believe that these discussions should be had with a family
member. Most striking is that most Canadians believed they should
think about or at least discuss end-of-life care while they are in good
health.9 The barrier between patient and physician seems to be a
problem of initiating the discussion in a manner which causes the
least amount of stress for the patient.10 Yet, the physician requires
an appropriate and a comprehensive strategy to be able to approach
these discussions. There is no effective check-list approach to ACP.
There exist some forms of checklist to facilitate discussion. However, death is shared universal event that is experienced very differently amongst individuals and their families.8 Successful ACP is
reliant on a shared approach of open and honest communication
between physician and patient.11
Critical care physicians often engage in family meetings and
are perceived to have some degree of competence in eliciting patients’ wishes and facilitating decisions during the end-of-life period. The checklist approach to family meetings is one that does not
consider individual patient experiences or prior knowledge of their
disease and medical interventions like invasive monitoring and
mechanical ventilation. Research by Scheunemann et al examined
transcripts of 71 recorded family meetings. The findings suggest
that a patient’s values and preferences are explored poorly in discussion with surrogates. Patient preferences were not discussed at
all in 30% of family meetings. Values like independence, known to
be highly important to patients, was not discussed in 88% of those
meetings. Yet, clinicians made explicit recommendations in 61% of
conferences. The study has obvious limitations, so the results cannot be extrapolated to all patients and every ICU setting.11,12 The
study was performed in two ICU settings in California. The authors
purport that they observed younger physicians who specialize in
internal medicine or neurology. The Hawthorne effect can also not
be excluded. These physicians knew they were being observed for
the purpose of study. Thus, the variety in physician behaviour and
approach was not fully captured in this study. What can be inferred
is the fact that physicians may not always be considering their patients’ wishes and values.12
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conclusion
The shared care model of ACP, between patient and physician
is something that needs to be examined further and expanded upon.
Clinicians may not have elicited patients’ wishes because of time
constraints or a fear of upsetting the patient. Patients may be fearful
to initiate the conversation and are simply waiting for a trigger to
come along. In the context of patient-centred care, patients present
with an issue and it is the responsibility of the clinician to assess and
manage the complaint. If healthy patients were regularly prompted
to think about end-of-life care in cooperation with their health care
provider, it is likely that we would be better able to preserve some
dignity in death by avoiding costly and unnecessary hospitalization.
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Modifications in anesthesia for geriatric patients
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abstract
The volume of geriatric surgery is expected to increase dramatically by 2020, requiring a more widespread appreciation
of the unique risks and challenges of anesthesia in the elderly.
Changes in pharmacokinetics along with age-related changes in organ function have important implications for patient
monitoring and dosing of anesthetic, analgesic, and sedative
medications. Preoperative screening for risk of postoperative
morbidity is improved with an assessment of activities of daily living, and regional anesthesia may be considered to reduce
the risk of postoperative delirium, although this remains controversial. Specific homeostatic parameters should be closely
monitored in the perioperative period. The approach to anesthesia in geriatric patients should not be merely extrapolated
from younger patients, and further evidence specific to geriatric anesthesia will improve surgical outcomes.

It is no secret that our population is aging, with an estimated
50% increase in the over-65 population by 2020 from 2001. Older
patients also have invasive procedures at nearly quadruple the rate
of younger patients, particularly in ophthalmology and cardiology
(9- and 2.5-fold, respectively).1,2
Across a variety of surgical procedures, a linear increase in the
absolute risk of surgical morbidity is observed with age, increasing
from 11% in 20-29 year old patients to 49% in octogenarians. Surgical mortality increases exponentially with age, with a dramatic
increase from the fifth decade of life, reaching 6% in octogenarians
as compared to 0.4% in patients in the 20-29 year old cohort. While
the prevalence of risk factors is correlated to age, age remains an
independent risk factor for postoperative morbidity and mortality.3
As human physiology changes with age, it has been widely
shown that pharmaceutical drugs have correspondingly modulated
pharmacokinetics. The drugs in the anesthesiologist’s arsenal are
no exception, and this article will review concerns that the anesthesiologist must take into consideration when treating the geriatric
patient. More specifically, this article will discuss considerations
for planned surgeries, rather than emergent operations, in order
to focus on the importance of preoperative screening and proper
follow-up.

physiological changes of aging
Pharmacokinetic changes in drugs
There are important age-associated body compositional
changes with implications for pharmacokinetics. Reduced relative
water content and increased fat percentage result in a higher serum drug concentration after bolus injection and longer half-lives
for lipid-soluble drugs. Declining cardiovascular function can slow
drug delivery to tissue sites, resulting in a slower onset of action.
UWOMJ 84:2 | Fall 2015

Decreased albumin content and protein binding results in a higher
volume of distribution of acidic drugs. The opposite is seen for alkaline drugs.4
As the human body ages, gradual deterioration of all body
systems also results in reduced hepatic and renal metabolism and
excretion, impaired cardiovascular distribution and disrupted fluid homeostasis. Although the liver and kidneys display minimal
structural changes with aging, it has been found that P450-dependent oxidation decreases, meaning that hepatically cleared drugs
(eg propofol) have a longer half-life.4
Pharmacodynamic changes in drugs
Decline in cardiovascular health, especially through stiffening
of the blood vessels and cardiac decline, is a leading risk factor for
peri- and postoperative morbidity. Cardiac decline describes diastolic dysfunction and an increasing dependence on sympathetic
drive and the Frank-Starling mechanism. Increased central nervous
system dependence of cardiac function often manifests as a marked
decline in blood pressure with anesthesia induction.4
Inhaled anesthetic agents such as sevoflurane and desflurane
remain agents of choice for North American anesthesiologists, despite the still-unclear mechanism of action. It is therefore important to recognize that inhaled drugs have a decreased minimum alveolar concentration (MAC) in geriatric patients due to a greater
sensitivity; whereas the MAC of isoflurane in the pediatric patient
is 1%, it is 0.25% in the 95-year-old patient. Geriatric patients also
exhibit a higher sensitivity to opioids and benzodiazepines, so it is
important for the anesthesiologist to carefully titrate administration of narcotics to minimize toxicity while maintaining effective
pain management.4,5

practical considerations in the or
Since geriatric patients are often receiving polypharmaceutical
treatment, it is important to conduct physiologic optimization and
to minimize premedications (eg heparin, diuretics). Preoperative
risk factors (eg hypertension, dyspnea) have been identified to be
more important than intraoperative events (eg transient hypoxemia, apnea) in predicting postoperative morbidity.
While preoperative screening is common practice in most
centres, it is important to be more thorough with elderly patients
and to complete a comprehensive history and physical exam. Many
abnormal lab values, including anemia, creatinine, and hyperglycemia, are less effective than history and physical examination at
predicting postoperative morbidity.6,7 To that end, a geriatric assessment is recommended for elderly surgical patients; 6 questions regarding activities of daily living and instrumental activities of daily
living have been shown to identify 98.5% of elders with postoperative morbidity (Table 1).8
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Table 1: Sample 6-Item Pre-Op Questionnaire6
Ascending/descending stairs
Urine continence
Walking in a corridor
Bathing
Shopping
Food preparation

Postoperative monitoring
It is important to be aware of postoperative morbidities such
as cardiovascular damage and stroke. Intraoperative complications,
which happen in 20% of geriatric patients, lead to a 6-fold increase
in morbidity. Hospitalization has also been identified as a risk factor
for postoperative morbidity, so when possible, outpatient surgeries
are especially recommended for geriatric patients as this generally
reduces nosocomial risk in all patients. Finally, since delirium and
dementia can also occur in the geriatric population after anesthesia, it is important to monitor for changes in mental status during
follow-up.7,11

conclusion
Perioperative considerations and patient management
Control of body temperature is essential for successful surgery as anesthesia can lead to hypothermia. This effect is further
pronounced in the geriatric patient because baseline hypothalamic
function often declines, leading to impaired thermoregulation, especially with general anesthesia. Since even mild hypothermia can
lead to infection or myocardial infarction, the anesthesiologist must
be particularly vigilant with maintenance of body heat in the elderly.9
Because age-related deterioration of renal and cardiac function
negatively impacts fluid homeostasis, it is prudent to carefully monitor blood pressure when administrating IV fluids and to be watchful for renal overload. It is particularly important to meticulously
pay attention to water balance, drug dosing, and maintenance of
normal intravascular volume to keep patients healthy.10
Changes in pulmonary physiology also result in increased physiologic dead space due to compliant airways, so minute ventilation
should be increased, and positive end-expiratory pressure can also
be considered. Nasal cannulas are also indicated for virtually all elderly patients due to declining respiratory function and reserve.9
As suggested above, the recommended doses for drugs are
nearly globally decreased in the elderly. A more comprehensive table is provided (Table 2).5
Table 2: Recommendations for Dosage Adjustment Consequent to Altered
Pharmacokinetics and Pharmacodynamics in the Elderly5
Class of drug

Dosage adjustment

Barbiturates

Modest reduction in bolus dose and infusion rates

Etomidate

Reduction of up to 50% in bolus dose

Propofol

Reduction of 30-50% in bolus dose and infusion rates

Benzodiazepines

Reduction of up to 75% in bolus dose and infusion rates

Opioids

Reduction of up to 50% in bolus dose and infusion rates

Non-depolarizing
neuromuscular
blocking agents

No reduction in bolus dose, but generally reduced infusion rates depending on the drug

Volatile agents

Reduction in inspired concentrations of 6% per decade
of age

Local anesthetics

Small to moderate reduction in segmental dose
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With the geriatric population projected to increase, compounded with an increasing rate of surgery and of morbidity/mortality risk in patients over 65, it is important to understand the concerns about anesthesia in elderly patients and to appreciate where
extra vigilance is required. Due to a global decline in physiological
function and reserve, drug pharmacokinetics are often severely affected. Declining fluid and temperature homeostasis also imposes
more responsibilities on the anesthesiologist. Finally, certain classes of drugs, such as opioids and inhaled anesthetics, demonstrate
a markedly increased potency in the elderly patient, necessitating
careful titration to avoid toxicity. The field of geriatric anesthesia is
increasing in importance because extrapolation of knowledge from
younger patients may not accurately apply to elderly patients. Best
practice guidelines may need to change as more geriatric-specific
evidence emerges in the coming years.
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introduction
Frailty is a term often used by both medical experts and laymen, yet defining the concept proves to be more difficult. Frailty is
not just aging, though its prevalence increases with age.1 A person
who is frail may show no symptoms of disease, no co-morbidity, nor
disability, but is more susceptible to rapid decline in the event of
illness. Then how do physicians track this condition and communicate accurately with colleagues? And what are the implications of
frailty and its clinical significance?
In broad terms, frailty is a constellational phenomenon consisting of weakness, aging, declining physiologic reserve, and impaired
cognitive capacity. This increased vulnerability from age-associated functional decline results in a reduced ability to cope with everyday or acute stressors.2 Although loosely defined, frailty has been
found to be a prognostic indicator of recovery after illness, hospitalization, and surgery.

definitions
Currently, there are at least 27 different measurements of frailty described in literature, each with its own focus and advantages.3
Depending on the definition, the prevalence of frailty in people age
65 or greater is estimated to be around 10.7%.4 It increases with age
and with chronic comorbid conditions. However, there is currently
no consensus on a preferred definition. Here we introduce a few
common ways that physicians characterize frailty.
The Frailty Phenotype (FP) is defined as having 3 or more of
unintentional weight loss (≥ 10 lbs or 5% body weight per year), grip
weakness (≤ 20th percentile), exhaustion (self-reported), slow gait
velocity (≤ 20th percentile), and low physical activity (based on a
questionnaire).5 It is shown to be an independent prognostic factor for falls, worsening activities of daily living, hospitalization, and
death. While FP provides a concrete definition, some of its components such as grip strength measurement are more technical. Also,
the physical activity questionnaire is time consuming, making FP
less practical for routine clinical use.6 Since then, a variety of more
clinically friendly tools have been developed.
One of these tools is the Clinical Frailty Scale (CFS). CFS evaluates the presentation of frailty on a scale of 1 to 7, taking into account
mobility, assistive devices, energy level, comorbidities, physical activity, and functionality.7 A series of pictographs is even available to
facilitate the diagnosis. A recent study assessed a group of seniors
using both the CFS and the Frailty Phenotype, and concluded that
the 2 tools have a high concordance.6
In general, a frailty assessment involves functional evaluation
along with other indicators to form a comprehensive picture. The
“timed up and go” test is a classic motor assessment that involves
a patient rising from a seated position in a chair, walking 3 meters
forward, turning around, then walking back to the chair and sitting
UWOMJ 84:2 | Fall 2015

down.8 This test requires both static and dynamic balance and is
closely related to mobility in everyday life. Moreover it is quick and
can be easily included in the comprehensive geriatric exam.
Combining motor function and other indicators, a variety of
frailty indexes have been proposed, including one outlined in the
Survey of Health, Aging and Retirement in Europe (SHARE), a population-based longitudinal study. The criteria include reported fatigue, low appetite, weakness, observed gait (walking without help,
with help, chair-bound, bed-bound, unobserved), and low physical
activity. The SHARE frailty instrument also correlates with overall
mortality.9

pathophysiology
One of the hallmarks of frailty is a decline in physiologic reserve. A number of systems are affected, such as the musculoskeletal, endocrine, immune systems, and the brain.10 Sarcopenia, for
instance, directly contributes to the decline in functional ability.11 In
the endocrine system, changes in insulin-like growth factor (IGF),
sex hormone, and cortisol secretion are also associated with frailty.12 Cognitively, frailty is associated with a higher incidence of mild
cognitive impairment in the elderly.13
Moreover, frailty is an inflammatory state.14 The frail elder has
chronically elevated levels of inflammatory markers compared to
robust older adults. Interleukin 6 and C-reactive protein are present in low grade inflammation, and are associated with morbidity in
the geriatric population. But it is uncertain whether frailty leads to
inflammation or vice versa. This inflammation leads to a catabolic
state contributing to weight and muscle loss.15 Furthermore, antibody responses to vaccinations are reduced, leaving frail patients at
an increased risk of contracting infections such as influenza.16
The causes of these physiological changes are complex. Frailty
upsets the delicate balance of homeostasis, leading to loss of physiologic reserve. With more research into the pathophysiology of
frailty, biological markers may potentially be combined with functional assessment to evaluate frailty in the clinic.17

implications
Slow gait speed, low physical activity, weight loss, and cognitive impairment are associated with chronic disability, long-term
nursing home stays, and mortality.18 Hospitalized patients who are
frail have increased risk of developing delirium.19 Preoperative frailty is associated with higher postoperative complications, length of
stay, and discharge to assisted-living facilities.20 Kidney transplant
recipients who are frail have delayed graft function.21 Thus, assessing frailty is important in planning elective procedures and during
the course of hospital stay. It can also serve as a prognostic factor
for expected patient recovery.
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After a patient is recognized to have frailty, there are ways to
slow its progression. Currently, medications and hormone supplementations are not recommended,22 but avoiding polypharmacy is frequently beneficial.23 Interventions mainly involve lifestyle
changes and supportive care.24 For example, nutritional counselling
and micronutrient supplementation can help maintain weight.25
Resistance exercises can be prescribed to strengthen hips and
knees.24 Finally, home visits, social support, and outpatient care together construct a holistic patient centered environment for frail
patients.26

conclusion

10. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in

11.

12.
13.

Frailty is an important condition affecting seniors, and contributes to morbidity and mortality during the course of medical care.
There are many definitions of frailty. However, there is not yet a
consensus for any single set of diagnostic criteria.27 We must recognize that frailty is a complex medical condition. The various criteria
assess this condition from different angles, such as muscle strength,
cardiovascular status, and activities of daily living. Physicians need
to weigh and balance these perspectives and keep in mind the larger picture when making clinical decisions for their patients, such as
whether or not to perform elective surgery. In an aging population,
physicians will be taking care of an increasing number of elderly patients. The recent increase in literature on frailty reflects its
growing recognition and importance. Thus, an understanding and
appreciation of the evaluation, impact, and management of frailty is
critical to future health care in Canada and around the world.
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background
Geriatric patients are often underrepresented in clinical research,1 in part due to underrecruitment and to their often arbitrary
exclusion from trials.2,3 Recruitment is especially difficult in older
patients with language barriers, access barriers to leaving the home,
and diseases that impair decision-making capacity.1,2 The paucity of
geriatric research is troubling given Canada’s aging population,4 as
research findings in younger study participants may not be generalizable to older patients.5 This lack of evidence is problematic for
health care providers, who must decide whether prescribing certain treatments to older patients is appropriate without the proper
evidence base.1
Unique ethical and legal challenges exist surrounding recruitment of incapacitated older patients, specifically within the context
of dementia. Between 44% and 67% of patients with mild-to-moderate dementia do not have the decision-making ability to consent
to participating in research, and all patients with severe dementia
are considered incapacitated.6 However, their inclusion in research
is essential to furthering investigators’ understanding of dementia. For example, both cerebrovascular and cardiovascular disease
(CVD) have been associated with cognitive decline; without the
participation of patients with late-stage dementia, researchers cannot thoroughly investigate how CVD influences the progression of
cognitive decline or, contrarily, how dementia may put a patient at
risk of CVD.7 This article explores how older adults with dementia
may be included in clinical research while protecting these older
adults from coercion or harm.

legal standards for decision-making
In considering the legal challenges of geriatric research in incapacitated older populations, it is important to first define capacity. Although not a universal definition, the “four abilities model”
devised by Appelbaum and Grisso describes four criteria to define
legal standards of capacity: being able to reason about options, communicating a decision, understanding the context of that decision
and appreciating its foreseeable consequences.6,8,9 Many patients
with dementia do not meet these standards of capacity and are
thus unable to provide consent themselves when participating in
research.6,10 In Canada, the Tri-Council Policy Statement (TCPS)
on Ethical Conduct for Research Involving Humans dictates that
only a substitute decision-maker (SDM) who is not part of the research team may authorize an incapacitated adult’s participation in
research.11 Although the SDM’s consent is required for participation, the patient’s dissent (ie objection) to participation overrules
the SDM’s decision.11,12 Therefore, investigators should provide incapacitated patients with as much information about the trial as
UWOMJ 84:2 | Fall 2015

patients’ understanding will allow, in an effort to obtain their affirmative agreement, otherwise known as their assent.13 In the context of dementia, assent is defined as the ability to express a choice
and at least a minimal understanding of the information provided.
The inability to communicate a choice and thereby provide assent
does not preclude a patient with dementia from participating in research; however, assent is required for patients who have this ability, and dissent to participation is unequivocal.12
The TCPS also states that incapacitated adults may only be recruited for research specifically requiring their participation (eg an
Alzheimer’s disease treatment study) and involving either minimal
risk or risk that is outweighed by potential direct benefits.11 These
standards parallel the protective measures in place for paediatric
research.14 There is no clear threshold of when potential risks outweigh direct or indirect benefits. Thus, to balance scientific inquiry
with protection of patients, review of protocols for research of incapacitated older adults must consider broad risk-benefit categories,
and protocols with no anticipated benefits to study participants require more conservative risk-benefit analyses.10

ethical considerations
The decision to include an older, incapacitated participant in
research must respect that individual’s values and address principles of beneficence, non-maleficence and justice.15,16 There is disagreement in the literature regarding the most ethical approach to
making this decision. Two commonly considered approaches are
“best interests” and “substituted judgments”. In substituted judgments, the SDM makes a decision based on what the participant
may have believed, thereby aiming to respect the participant’s values and wishes. A concern with substituted judgments is that often
an SDM may be unaware of the patient’s prior wishes since consent
to research is not routinely incorporated in a patient’s advance directives.17
In contrast to substituted judgments, which emphasize the patient’s prior wishes, “best interests” values the SDM’s opinion on
what is best for the patient. “Best interests” aims to maintain the
older adult’s quality of life and avoid unnecessary harm, should the
intervention pose risks.17 Making this judgment is challenging in
the case of established treatments and becomes even more so when
evaluating an experimental treatment with unknown risks and benefits. Another concern with this more paternalistic approach is the
possibility of the older adult’s previous wishes being disrespected.
With either approach, it is very difficult to determine whether
a person without the ability to consent would be interested in therapies with potential risks that may prolong life without improving
quality of life.15-17 However, the potential benefits of this research to
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patients with dementia cannot be uncovered unless resources are
justly allocated towards studies involving this population of incapacitated older adults.

11. Canadian Institutes of Health Research, Natural Sciences and Engi-

future directions and concluding remarks
In the context of research involving older, incapacitated adults,
be it with dementia or other mentally impairing diseases, the best
course for recruiting patients is not clear. Inclusion of incapacitated
participants is essential to enhancing our understanding of dementia and might have direct neurological benefits on these individuals.6,10 However, SDMs face the challenge of weighing the risks and
benefits of clinical research to their relative, often having to speculate what their relative’s wishes would be.17 To address this concern,
interest in research trials should be discussed with individuals with
early dementia while they are still able to decide for themselves.
Involvement of incapacitated older adults in research trials
may also be improved by training research personnel on evaluating
capacity,6 by avoiding arbitrary upper age limits in protocols and
by addressing access and transport requirements of older adults.2
Additionally, expanding academic geriatrics and involving a greater
number of geriatricians on research boards would help to promote
geriatric research overall.1
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Modifying the healthcare system to
accommodate our aging population
Adam Kovacs-Litman (Meds 2018), Michael Hewak (Meds 2016)
Faculty Reviewer: Dr Chris Brymer, MSc, MD, FRCPC (Division of Geriatric Medicine)

In the last 150 years, advances in the field of medicine have extended the average lifespan in the Western world by over 3 decades1
and this trend shows no signs of slowing down. If current forecasts
are accurate, a third of all babies born in the Western world today
will live past their hundredth birthday.2 A century ago, this demographic shift had primarily been due to reduced infant mortality
and better infection control, and this trend has continued more recently due to better management of chronic conditions like cancer
and heart disease.1 Nearly half of provincial/territorial government
healthcare spending is allocated to seniors (those 65 years of age
and older), but our aging population will only cause this proportion
to increase, likely reaching unsustainable heights.3 This ongoing
demographic shift will force us to balance economic sustainability
with the effective care of seniors in hospital, postdischarge, and at
end-of-life.
A report by the Canadian Institute for Health Information illustrated the current financial burden of seniors on the healthcare
system quite handily. While adults aged 15-64 cost our healthcare
system an average $2286 per capita annually, health spending on
seniors was $10 742 per capita. Furthermore, the financial cost for
those seniors aged 80 years and over cost the system a staggering
$18 160 per capita.5 This provides a significant challenge for our
healthcare system, as it is projected that over the next 25 years, the
proportion of the Canadian population 65 and over will jump from
14% to 25%.4
Although longevity is expensive, technically speaking, it is not
age itself that increases healthcare expenditure but rather the number of chronic diseases an individual possesses, which tend to rise
with age. Indeed, between 50-60% of seniors suffer from three or
more chronic diseases, compared to 15-30% of those aged less than
65 years.6 Most chronic conditions are self-managed by patients and
their families at home until patients are typically in their late 70s.
Unfortunately, while hospitals are often exceptional at treating patients with acute conditions, their management of patients who require chronic care is often fraught with inefficiency, fragmentation,
and poor outcomes.3,7
Alternatively, long-term care (LTC) facilities are structured
around the rehabilitation and continued management of patients
with these chronic and often deteriorating conditions.8 They are
institutions designed to fill the gaps created by our hospital-centric system, yet they are woefully underutilized by policy-makers.
Though the plan is always to transfer chronic patients to LTC or
home care, our system is ill-equipped to meet this growing demand.
In Ontario alone there are 2000 waiting in hospital beds for LTC.
Of the 1000 of these waiting in acute care hospital beds, three quarUWOMJ 84:2 | Fall 2015

ters will be placed in LTC within 10 months; however 15% will pass
away while on the wait list. And this demand-supply mismatch is
only getting worse with the median wait time tripling from 2005 to
2012.9 What makes this issue even more frustrating is that one day
in a hospital costs the province approximately $1000, while comparable LTC costs only $137.10 and homecare just $55.11. Focused
investment in LTC would not only improve patient outcomes for
the chronically ill, but also save the healthcare system money by
freeing up acute care beds, thereby allowing hospitals to better treat
those with acute illness.
Seniors with chronic needs occupying acute care beds is a
ubiquitous problem in our healthcare system that will only worsen
as our population continues to age. The term “Alternate Level of
Care” (ALC) describes this phenomenon—patients who have completed the acute phase of their management in hospital, yet continue to occupy an acute care bed. Currently, seniors comprise 40%
of acute hospital stays in Canada, and of the 85% of such stays that
were designated ALC, nearly half were waiting to be placed in an
LTC facility.12
At Mount Sinai Hospital in Toronto, a program called the Acute
Care for Elders (ACE) Strategy has shown great promise as a model
for streamlining senior care and reducing the number of ALC patients. The premise of ACE is to implement a higher level of integration across the multiple modalities of healthcare and social services
a patient might be receiving across a variety of locations—namely
the home, community, and hospital. For example, part of ACE involves screening seniors who present to the emergency room for
risk factors that might predict poor outcomes, then adjusting both
in-hospital and postdischarge care accordingly. Specialized inpatient geriatric consultation teams manage issues that contribute
to functional decline, and aim to avoid hospitalization altogether
if possible. Upon discharge, patients are meticulously followed and
receive ongoing homecare via partnerships with local organizations, geriatricians, and geriatric psychiatrists. In just one year, the
project saw tangible reductions in average length of hospital stay
and hospital readmission rates, and patient satisfaction with this
program was polled at 97%.3 The cost and cost effectiveness of the
resources required to achieve these gains has not been determined
yet, however.
Studies have shown that within 30 days of being discharged
from the emergency department, 8% of seniors are either readmitted to hospital or die, with an additional 16% returning to the
ER.13 Integrated care systems such as ACE have been shown to keep
seniors at home, reducing stress on the healthcare system by decreasing the quantity and length of hospitalizations, while simultaPage 16
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neously improving the level of access and quality of care received.
The first four years of PRISMA, a similar integrated care project
in Quebec, found a 50% reduction in unmet medical needs, a 20%
reduction in ER visits, a significantly reduced number of hospitalizations and a 14% decrease in individuals experiencing functional
decline.14 Again, the economic sustainability of this program has not
been established.
It is clear that medicine works best when it is integrated as
part of a multidisciplinary care system that is organized around the
needs of the individual, but integration can come in many forms.
Several studies suggest that case managers may be an invaluable
tool in facilitating the care of the aging population. These are individuals (often nurses) who coordinate care from different providers, ensure that communication is maintained between members of the patient’s healthcare team, and educate patients on what
care they require and how to go about getting it. Furthermore they
would arrange, coordinate, and oversee the home care for hospitalizable conditions such as pneumonia, congestive heart failure, and
COPD. A trial of such a project in Australia involved assigning seniors a case manager to oversee their medical care, and resulted in
21% fewer ER visits and 28% fewer hospital admissions.15
The nuances of palliative care are another area where the hospital machine seems to fall short. The human condition is in part
defined by our remarkable ability to hope even in the face of tremendous adversity, even in the face of hopelessness. Broaching the
subject of palliative care seems to run contrary to our nature, forcing both healthcare providers and patients to address the uncomfortable subject of death. However, talking about death demystifies
it and allows patient preferences to take shape. A randomized control trial looking at lung cancer patients found that those offered
palliative care reported improved quality of life at 12 weeks.16 As
guidelines continue to emerge and healthcare provider education
improves, this is an area where we will continue to improve.17,18
There was a time when most people died at home surrounded
by their families—familiar faces in a familiar environment. Approximately 64% of people die in hospitals while another 12% pass away
in LTC facilities.19,20 This sadly does not accurately reflect patient
preferences, as literature shows that the majority of seniors prefer
to die in their own home.3
As our population ages, palliative care will give the medical
profession a tremendous opportunity to put the dignity back in
dying, allowing people to pass away comfortably and with meaning. Talking about palliative care is a first step. The next step is to
humanize death by listening to patients, helping them realize and
articulate their preferences. This will not only improve the quality
of a patient’s last few months, but also relieve stresses on hospital
resources, allowing for more effective care of other patient populations. The availability and flexibility of hospice and palliative home
care, however, is a major factor in whether it is even feasible for end
of life to occur at home.
The organizational, economic, and political complexity of implementing such significant shifts in the structure of our healthcare system is daunting, but necessary. As more research is done
to elucidate the most cost-effective and patient-centered methods
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of accommodating the rapidly changing demographic landscape,
we expect to see increased funding and manpower being allocated to expanding LTC facilities. Further, we expect a greater focus
on the use of programs and case managers that integrate each patient’s unique mix of medical and social services. We also anticipate
a greater emphasis on patient preference at end-of-life, and the development of better palliative care options. What is certain is that
Canada’s demographic landscape will see unprecedented change
in the coming decades as medicine pushes the limits of the human
lifespan beyond what was previously imaginable. The question that
remains to be answered is how our healthcare system will manage
to adapt to meet our aging nation’s rapidly evolving medical needs.
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introduction
On February 6th, the Supreme Court of Canada ruled that the
century-old law condemning assisted suicide was unconstitutional.
This momentous ruling now opens the door for physician-assisted
suicide.1 This decision has left many wondering how this will affect
geriatric, palliative, and end-of-life care in Canada. The ruling has
been met with much controversy, leaving both physicians, and the
public unsure how to apply these new rulings to everyday medicine.
The terms “euthanasia” and “physician-assisted suicide” (or some
variant thereof ) have been used to describe the potential consequences of the ruling in the media, though these terms should not
be obfuscated. These are two distinct acts, though this ruling makes
both permissible. Materstvedt et al defined physician-assisted suicide as “a doctor intentionally helping a person to commit suicide
by providing drugs for self-administration, at that person’s voluntary and competent request.”2 Conversely, euthanasia is outlined
as “a doctor intentionally killing a person by the administration of
drugs, at that person’s voluntary and competent request.”2

history of physician-assisted death
Prior to the Supreme Court ruling, the role of Canadian physicians in assisted suicide was clear. Criminal Code of Canada
section 241(b) states “everyone who […] (b) aids or abets a person
to commit suicide, whether suicide ensues or not, is guilty of an
indictable offence and is liable for imprisonment for a term not
exceeding fourteen years.”3 The ethics surrounding physician-assisted suicide, however, are less clear. Many physicians currently
employ the principle of double effect when taking care of palliative patients. In essence, double effect is the administration of any
medication, often narcotics or sedatives, with the intent to palliate
dying patients even though the administration of these drugs may
hasten death. Interestingly, in places where physician-assisted
suicide is forbidden, a “medical death” hastened by palliation is
typically permissible.4 It is the intention that is most important in
these cases as the physician is not intending to end life but rather
chooses to focus on patient comfort at the expense of known drug
side effects.
Physician-assisted suicide is inextricably linked to geriatric
care. In 1997, Oregon legalized physician-assisted suicide. In the
first year of legal physician-assisted suicide, the median age of
physician-assisted suicide patients was 69, well within the jurisdiction of geriatrics.5 Of these patients, 86% had cancer, 21% were
completely disabled, and all were terminally ill. A survey in the
Netherlands also found that physician-assisted suicide occurred
predominantly in elderly populations, with a median age of 71.
UWOMJ 84:2 | Fall 2015

Surveys have also shown that elderly people would choose to undergo physician-assisted suicide to prevent becoming a burden to
their families or others. These patients were quoted as saying, “I
wouldn’t want to become a nuisance under any circumstance.”
This provides some qualitative insight into why some healthy older individuals might support medical practices that hasten death.
In the Netherlands, roughly 17% of patients request physician-assisted suicide because they are “tired of living” and 25% of those
had no serious disease or no disease at all.6
Opinions on physician-assisted suicide are divided among
physicians themselves. Many physicians believe that patients have
a right to die with dignity, or that patients have a fundamental
right to autonomy over their bodies. They may also want to help
to alleviate the suffering endured by their patients with intractable or terminal diseases. Conversely, many physicians see physician-assisted suicide as a sign that current palliative care is inadequate. They may also believe that physicians should not take on the
role of executioner. In addition, there is significant concern about
the potential for abuse of power by physicians.

the supreme court ruling
The Supreme Court ruling has profoundly altered the landscape of physician-assisted suicide. The court ruled “prohibition of
physician-assisted dying infringes on the right to life, liberty and
the security of the person.” The ruling states that adults who are
enduring intolerable suffering can consent to ending their own
lives. The court found that a person’s response to an irremediable
medical condition was a matter of dignity and autonomy. As well,
“by leaving people […] to endure intolerable suffering, it impinges
on their security of the person.” The court also highlighted the fact
that in jurisdictions that have legislated physician-assisted suicide
such as Oregon and the Netherlands, the safeguards put in place
have been effective. In an unusual move, all 9 justices shared credit
for the ruling, a move intended to lend institutional weight to the
ruling. Technically, the court has given the federal government 12
months to write legislation to respond to, or attempt to overturn,
the ruling. If legislation is not put forth, physician-assisted suicide
will be in a situation similar to that in which abortion resides: legal
and left to the medical profession to regulate without government
oversight.1
The ruling is not limited to those who might require assistance
to end their lives, for example patients suffering from amyotrophic
lateral sclerosis (ALS). It is unclear whether an intractable psychiatric condition might qualify as an “irremediable medical conPage 19
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Instead, it is left up to physicians and lawmakers to determine what
qualifies as “enduring and intolerable suffering.” Under the new
ruling, physicians are not compelled or required to help patients
end their lives, it merely removes prohibitions against it.1 The Canadian Medical Association (CMA) is presently encouraging physicians to “follow their conscience” when making these decisions.7

the role of the cma
The CMA has been bracing itself for this decision. For a year
and a half, the organization has been debating and researching how
to best handle physician-assisted suicide. As the president of the
CMA, Dr Chris Simpson acknowledges physician-assisted suicide
requires physicians to make decisions that go to the “very gut of one’s
personal ethics and morals.”8 The CMA organized town halls and
reviewed physician-assisted suicide practices in other countries,
most notably Oregon and the Netherlands. In August 2014 at the
CMA’s annual general meeting, members voted 91% in favour of a
motion to allow physicians “to follow their conscience when deciding whether to provide medical aid in dying.”9 Although this is not a
formal regulation, it speaks to the general consensus of physicians’
opinions on physician-assisted suicide regulations. This resolution
also signals a changing of policy for the CMA, an organization historically opposed to both euthanasia and physician-assisted suicide.

the changing role of the geriatrician
The emphasis on quality of life in end-of-life care and advanced
planning discussions suggest that geriatricians will be at the center
of the physician-assisted suicide discussion. Geriatricians focus on
holistic, person-centered care, which often centers on quality of life
rather than its duration. Geriatricians often decrease pill burden in
patients who would rather take fewer medications, even at the expense of living for a shorter time, for the sake of fewer side effects.6
With the emphasis on holistic care and quality of life, physician-assisted suicide is well within the realm of geriatric medicine.
The question remains however, how will this new ruling change the
role of these physicians? It could theoretically alter the landscape
of the principle of double effect. This ruling may require geriatricians to discuss the option of physician-assisted suicide with their
patients suffering from irremediable medical conditions. As well,
physicians will potentially have to engage the families and the substitute decision makers of their patients, an unquestionably difficult
conversation.
On a personal level, this will require geriatricians to grapple
with their own moral and ethical opinions surrounding physician-assisted suicide. In a 2014 survey, only 27% of physicians reported that they would be “likely or very likely to participate in”
physician-assisted dying. To that point, many provincial regulatory colleges (in Ontario, the College of Physicians and Surgeons
of Ontario) require that physicians refer their patients to another
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doctor if they refuse to offer controversial treatments. Historically,
these treatments have included prescribing birth control and performing abortions. This list may now require expansion to include
physician-assisted suicide. As Dr James Downar, a palliative care
physician, explains, “we need to recognize that conscientious objection in this context can serve as a barrier and we need a very
robust system to make sure that the physician’s right to conscientious objection does not impinge on the patient’s right to receive
what would be a legal treatment.”8 This new Supreme Court ruling
will profoundly alter the practice and culture of geriatric medicine.

conclusions
The Supreme Court ruling declared that aspects of the Criminal Code were unconstitutional with respect to physician-assisted suicide. Prior to this ruling, the role of physicians in these cases
was clear: they could not participate. With this new ruling, however, the landscape has changed. Physician-assisted suicide is closely linked to geriatric medicine, as we have seen in Oregon and the
Netherlands. This new ruling may require that geriatricians discuss
physician-assisted suicide as an option with their patients. It will
certainly require geriatricians to reflect on their own beliefs surrounding physician-assisted suicide. This new ruling will reshape
the practice of geriatric medicine in Canada.
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“

In the midst of divisive public debates, we frequently look to
history and past epochs to gain guidance and understanding, to explore the genesis of our ideas and practices, and to critically compare them with alternatives.
— Ezekiel J Emanuel, MD, PhD1

the value of historical ideology
The article from which this idealistic quote was taken from
was published in 1994; however, one can question whether it was
ever a habit of human thinking in these past couple of centuries to
extract guidance from historical occurrences. CS Lewis in his 1955
book Surprised by Joy denounced the problem of “chronological
snobbery”, which he defined as “the uncritical acceptance of the
intellectual climate of our own age and the assumption that whatever has gone out of date is on that count discredited.”2 He cautioned of the danger of chronological snobbery in another book.
The premise was that if human civilization were currently heading
down the wrong path, it is imperative that we return to that ill-chosen junction and “restart” our history on the right path. However,
if we ignore the timeline of the previous stages of our journey, we
risk losing the opportunity to return and start over.3 Quoting now a
member of our own profession, Eugene F Cordell, President of the
Medical and Chirurgical Faculty of Maryland in 1904, he lamented
in an address that “it [was] rare to find the subject [history of medicine] even mentioned in the curricula of the medical schools.”4 He
then attributed this phenomenon to an unhealthy obsession with
novelty, the unwillingness to make time for reflection, and the increasingly utilitarian and mechanical nature of human mentality.
An appreciation of historical ideology is crucial to a rigorous
and unbiased study of that branch of geriatric medicine which is
so ubiquitous and fiercely debated: end-of-life care. This is because
end-of-life care is not only a medical science, but also a philosophy. It is a value-laden specialty with a complex past. Currently,
there exist several approaches to end-of-life care, and in every case
where a patient is enduring his or her last few days, these approaches seem to compete for primacy. Proponents of each argue for their
case, but rarely do they appeal to the historical values behind the
method. Yet it appears obvious that if we choose to use the term
“end-of-life care”, we should at least explore the ideas and motivations of the predecessors from whom we inherited the term. This
article will discuss 3 approaches to end-of-life care—palliative care,
life-sustaining therapy, and euthanasia—and illustrate how attention to the historical evolution of their philosophies can enrich our
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understanding of them. It is hoped that the reader will emerge with
a deeper knowledge of the rationale behind each approach, as he or
she explores their genesis and development.

palliative care
Something can be learned about palliative care simply from
studying its linguistic roots. The term palliative derives from the
Latin verb palliare, meaning “to cover up” or “to conceal.”5 In the
context of healthcare, that which is covered up is the pain and suffering associated with end of life. The first record of palliative care
came from 4th-century Rome, where a Christian matron named Fabiola opened her home to pilgrims, the sick, and the destitute.6,7 She
called her home a “hospice.” During the Middle Ages, it became a
Christian tradition to take in the sick, poor, pilgrims, and crusaders.
While none of these primitive hospices cared specifically for the
dying, they do illustrate that the underlying principle of the earliest
palliative care was charity.
During the 19th and 20th centuries, hospices specializing in
end-of-life palliative care opened in France (1842), Dublin (1879),
and London (1905). But it was not until 1967 that Dame Cicely
Saunders established St Christopher’s Hospice in London, considered to be the first modern research and teaching hospice. It was
founded on three principles: openness, mind together with heart,
and freedom of the spirit. Saunders was trained first as a nurse, then
later as a physician. In her early days she cared for a terminally ill
cancer patient who endured a horrendous measure of suffering before his eventual death. Touched by their interaction, she came to
realize the importance of symptom and pain control for the dying.
At the same time, she saw an even higher need for the dying to come
to terms with their mortality, a goal which requires both emotional
and spiritual support.6
These historical revelations led to Saunders’ definition of “total
pain,” a term familiar to many ears today. This was a new model of
medical suffering which incorporated the biological, psychological,
social, as well as spiritual natures of the patient. After completing
her medical training, Saunders conducted an extensive amount of
research on palliative care. Her research style consisted mostly of
listening to patients and studying their narratives, by which she
was able to pinpoint the individual needs of every patient as they
lived out their final moments. Our capsule summary of Dame Cicely Saunders’ work shows that many concepts in modern palliative
care that we take for granted today derive from her philosophy. No
understanding of palliative care can be complete without a study of
her life and motivation.6
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life-sustaining therapy and euthanasia
The modern controversies surrounding life-sustaining therapy,
such as artificial nutrition or hydration and cardiopulmonary resuscitation, are anything but “new.”8 Due to advancements in medical
technologies and the management of chronic disease states as early
as the 19th century and early 20th century, there resulted a shift in
the culture of medicine from care to cure.9 Life-sustaining therapy
allowed medicine to keep a patient alive indefinitely in the hopes
of eventually finding a cure. However, in a desperate attempt at
cure, palliation of pain and symptoms is often sacrificed, a concept
recognized even in the 19th century. Simeon E Baldwin, in his 1899
Presidential Address to the American Social Science Association,
recounted the tale of a patient, terminally ill with stomach cancer,
who was sustained by injections of mutton broth. Her agony was so
great that “her stomach refused to retain anything but a little water;
and even that caused great pain.”10
On the other extreme of the end-of-life spectrum is euthanasia.
Whereas life-sustaining therapy aims to maintain life indefinitely,
euthanasia seeks to terminate life altogether in the face of suffering.
Although some may see euthanasia as a recent issue, referring to
its legalization in 2002 in the Netherlands, the ethics of euthanasia
has actually been debated for at least several centuries.1,11,12 Familiar
arguments for euthanasia include that it is a human right born of
self-determination and that it brings an end to suffering which has
otherwise no hope of alleviation. In fact, the Flemish Palliative Care
Federation believes that “euthanasia may […] be part of palliative
care.”13 Indeed, the philosophy of euthanasia emphasizes pain relief
and listening to patients’ individual needs, virtues seemingly in line
with historical values of palliative care.
Notably, much of the continued resistance to euthanasia may
also refer to historical sources. It has been questioned as early as
1936 whether euthanasia truly provides biopsychosociospiritual
support, as it essentially puts the patient that is being “supported”
out of existence.14 In the Netherlands, 33% of the patients who opt
for euthanasia do so because of a repulsion of being dependent on
others.15 However, this seems to defeat the entire underlying principle of the earliest palliative care, which is that people ought to help
one another in the name of charity.1
Therefore, modern arguments both for and against euthanasia
may in fact be rooted in historical philosophy. Proponents advocate
for pain relief and respecting patients’ personal needs, concepts established by Dame Cicely Saunders. Opponents question its true nature and whether it is really designed to support patients at the end
of life for the sake of charity. However, it is noteworthy that most of
those who support euthanasia do so with the intent of upholding
those values that form the foundations of palliative care. As shown
throughout history, the nature of end-of-life care evolved from an
innate desire to help, not to ruthlessly eliminate.

tensively debated, advocates of each option are eager to voice their
own opinions based on the most current research and experience.
However, they often forget that “no generation can bequeath to its
successor what it has not got” (CS Lewis),16 which implies that our
ideas and thinking are actually a product and accumulation of those
that came before us. By studying the quality of their philosophy and
arguments, we may come to a deeper understanding of both the
rigour and fallibility of our own. This is imperative in the exploration of end-of-life care, a branch of medicine possessing hundreds
of years of tradition and change.
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concluding remarks
The purpose of this article is not to promote an opinion on
which approach to end-of-life care is optimal. Rather, it is meant to
briefly foster an appreciation of the historical purposes and values
behind each approach. In a day and age where end-of-life care is in-
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abstract
Community-acquired pneumonia (CAP), most often caused
by infection with the Gram-positive diplococcus Streptococcus pneumoniae, remains a leading cause of death in Canada
amongst the elderly. With an aging population in Canada, CAP
will soon be a significant challenge to the healthcare system
in this country. In this article, we review the characteristics
of CAP in the elderly, including its epidemiology, etiology and
clinical features. We then provide an overview and history of
pneumococcal vaccines and present current recommendations
for S pneumoniae vaccination in Canada.

background
Pneumonia, primarily a result of colonization and infection by
the Gram-positive bacterium Streptococcus pneumoniae, remains a
dangerous disease with a high mortality rate, especially amongst
the elderly.1,2 Each year, approximately 200 000 people in Canada
contract pneumonia2 and around 5000 of those will die from pneumonia or complications related to pneumonia.3
Pneumonia can generally be divided into two major categories: community-acquired pneumonia (CAP) and hospital-acquired
pneumonia (HAP).4 Nursing homes, where a significant portion of
the elderly population in Canada resides, are considered community settings in the context of community- versus hospital-acquired
pneumonia.4 We will focus on CAP as a majority of elderly patients
with pneumonia contract their illness while in a community or in
nursing homes.1,4

epidemiology of community-acquired pneumonia
The overall incidence of CAP in Canada is estimated to be between 5.60 and 6.11 per 1000 people.2 A 2-year study at an emergency department in Edmonton, Alberta found that incidence was
significantly correlated with age.2 Incidence was found to increase
with patient age for patients over 50, reaching a maximum of 46.39
per 1000 in patients 90 and older. Incidence was also found to be
higher in men than in women in patients over the age of 70.2 CAP
is also the 7th leading cause of death in Canada,5 with an estimated
mortality rate of between 0.95 and 11.7 per 1000.3

etiology of community-acquired pneumonia
Microbes present in the upper airways routinely enter the lower airways. In the majority of cases, they are cleared by specific and
nonspecific host defense mechanisms, but when this clearance fails
to occur, pneumonia can result.1,4 Diverse factors that predispose
individuals to developing pneumonia, and these can be broadly di-
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vided into host immunocompromise, exposure to a particularly virulent respiratory microbe or inoculation with an overwhelmingly
large microbial load that overwhelms the immune system.4
The diagnosis of CAP in the primary care setting is for the
most part a clinical diagnosis, and the infectious etiology is often
poorly established.6 In a review of the literature, it was found that
a definitive microbial agent was established in only 24-67% of CAP
cases.6-10 Nevertheless, most studies agree that S pneumoniae is the
most common infectious agent responsible for CAP, being identified in 27.4 to 41.9% of CAP cases where a microbial etiology could
be established.6-10

pneumococcal pneumonia in the elderly
Risk factors
The elderly are at increased risk of developing pneumococcal
pneumonia.1,2 Specific risk factors that predispose the elderly to
becoming colonized by S pneumoniae include a depressed immune
system, increased prevalence of comorbidities, especially lung and
cardiovascular disease, and difficulty swallowing and aspiration.1
Clinical presentation
The clinical presentation of pneumonia in the elderly differs
from the “typical” presentation of a young adult with pneumonia.1,11
In particular, elderly patients with pneumonia tend to display fewer, or more subtle symptoms, with the authors of one study finding
an average of 2.9-3.3 fewer reported symptoms in patients over 65
years of age.11 In particular, there is a lower incidence of fever in elderly patients with pneumonia.11 In contrast, there are some clinical
comorbidities strongly associated with pneumonia in the elderly.
Most significant amongst these is dementia, which is present in up
to 41.1% of elderly patients with pneumonia.12
Management
Clinical guidelines recommend that elderly patients with
pneumonia be managed differently. All elderly patients presenting
with pneumonia should be assessed for clinical severity, using either the CURB-65 score (presence of confusion, BUN > 7mmol/L,
respiratory rate ≥ 30, systolic blood pressure < 90 and/or diastolic
blood pressure < 60, age ≥ 65)13 or the Pneumonia Severity Index
(PSI) developed by Fine et al,14 which is a more detailed guideline
to assessing severity of pneumonia.
The Canadian Thoracic Society currently does not recommend
different antibiotic regimens based on age. However, its most recent
guidelines specifically recommend treating nursing home residents
with either a respiratory fluoroquinolone alone or with amoxicillin-clavulin and a macrolide as the first-line empiric therapy.13
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streptococcus pneumoniae vaccinology
Overview
Pneumococcal vaccines come in 2 general categories.15,16 First
are the older polysaccharide vaccines, which consist of purified
capsule antigens.15,16 These polysaccharide capsule antigens are
recognized by B cell receptors, resulting in the generation of anticapsule IgM antibodies.16 There are a number of distinct drawbacks
to this strategy, including a lack of T cell antigen recognition and
resultant lack of isotype switching and production of the IgA antibodies that would be needed to confer mucosal immunity against S
pneumoniae.16
The newer generation of conjugated pneumococcal vaccines
consist of capsule antigen conjugated to an immunogenic diphtheria toxoid.15,16 This leads to recognition by Th2 cells and the induction of isotype switching by B cells and the production of both IgA
and IgG antibodies, and a stronger memory B cell response.16 In particularly, production of IgG is thought to be essential in the prevention of invasive pneumococcal disease.16 Unfortunately, the conjugated vaccine currently only contains a limited number of serotypes
as compared to the newest generation of polysaccharide vaccine.
History of pneumococcal vaccines
Pneumococcal pneumonia and its complications were major
sources of mortality before the widespread availability of antibiotics. Mortality rates in the 1920s and 1930s from pneumococcal
pneumonia and associated bacteremia and meningitis were well in
excess of 70% in hospitalized patients.15
Early efforts to develop a pneumococcal vaccine began in 1914
when British immunologist Sir Almroth Wright experimented
with the use of a crude whole cell vaccine in South African miners,
amongst whom pneumonia was epidemic.17 By the 1930s scientists
had advanced to the use of simple polysaccharide vaccines in small
observational studies.15 These studies paved the way for a number
of landmark controlled trials on bivalent, trivalent and tetravalent
pneumococcal polysaccharide vaccines in the 1940s that showed
for the first time that vaccination resulted in a drop in the incidence
of pneumococcal pneumonia.18,19
However, by the 1950s the attitude of the public and regulatory
bodies towards pneumococcal vaccines began to change with the
widespread availability of antibiotics.15 Pneumococcal vaccination
was thought to be unnecessary by regulators and it wasn’t until
the release of a landmark 1964 study by American infectious disease specialist Robert Austrian showing continued high mortality
rates amongst patients with pneumonia that interest in a pneumococcal vaccine returned.15,20 Austrian himself was at the forefront
of S pneumoniae vaccinology, creating the PPSV14 pneumococcal
vaccine, a polysaccharide vaccine against the 14 most common S
pneumoniae serotypes of the time, in 1970.21 PPSV14 was adopted
for widespread use in the United States by 1977 until 1983, when it
was replaced by the PPSV23 vaccine, which expanded coverage to
23 S pneumoniae serotypes.15
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Currently available vaccines
There are two pneumococcal vaccines currently available in
the United States and Canada. The first of these is PPSV23 (Pneumovax), a polysaccharide vaccine covering 23 serotypes, produced
by Merck.15,16 PPSV23 has been in used in the United States and
Canada for several decades and a number of studies of its efficacy
and safety have been published. A 2013 Cochrane review found that
available evidence showed PPSV23 was effective at prevention of
invasive pneumococcal disease (eg bacteremia, meningitis) but not
pneumococcal pneumonia.22
The second vaccine available is PCV13 (Prevnar-13), a conjugate vaccine covering 13 serotypes, produced by Pzifer.15,16 Conjugated vaccines for S pneumoniae have been available since 2000
in the form of PCV7, an early conjugate vaccine that provided coverage of 7 S pneumoniae serotypes. In 2011, PCV7 was replaced by
the newer PCV13,15 which was made available in the United States
under the US FDA’s Early Access program, reflecting the changing
paradigm of the pneumococcal vaccine from being thought of as
unnecessary by regulators to now being recognized as essential in
the reduction of pneumonia-related mortality. A large-scale clinical trial in nearly 85 000 patients (the CAPiTA study) sponsored by
Pzifer showed that PCV13 was 70% effective at the prevention of
invasive pneumococcal disease and 46% effective at the prevention
of pneumococcal pneumonia.23

current recommendations on s pneumoniae
vaccination in the elderly
Current recommendations on vaccination of the elderly against
S pneumoniae are based on those released by the US Advisory Committee on Immunization Practices (ACIP).24,25 For individuals 65
or older, the ACIP has recommended the administration of a single dose of PCV13 followed by a single dose of PPSV23 after 6-12
months.24 There is currently no evidence to suggest that revaccination with PPSV23 provides additional benefits.25

conclusion
Pneumococcal pneumonia continues to be a major source of
mortality for the elderly. The development of a vaccination program
against S pneumoniae has been a major step forward in the efforts to
mitigate the impact of pneumonia on the health of the elderly.
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abstract
Bilateral, end-stage, age-related macular degeneration
(AMD) is a devastating condition of the eye. As the leading
cause of blindness worldwide in the elderly, it leads to poor
quality of life. While antivascular endothelium growth factor
agents are used as front-line treatment for wet AMD, no current treatment exists for bilateral, end-stage AMD in Canada.
The implantable miniature telescope (IMT), approved by the
Food and Drug Administration in 2010, is a treatment option
available for those over the age of 65 in the United States with
stable severe to profound vision impairment (best-corrected visual acuity 20/160 to 20/800) caused by bilateral central
scotomas associated with bilateral, end-stage AMD. Combining the fields of engineering and ophthalmology, intraocular
implantation of the IMT provides improvements in patients’
functional vision and quality of life. As a relatively new treatment targeting the elderly, there are strict inclusion criteria as
well as risks associated with the procedure. However, research
and continuing development in this field is ongoing to minimize these risks.

age-related macular degeneration
Aging gracefully is a common goal amongst the elderly. Seniors
over the age of 65 capable of performing activities of daily living
(ADLs) such as walking and eating, as well as complex instrumental ADLs (IADLs), including driving and completing housework,
report having a better quality of life, less morbidity, and less mortality.1,2 Vision plays arguably one of the most important roles in carrying out ADLs and IADLs, but unfortunately vision impairments
are highly prevalent in the elderly population.2 Bilateral, end-stage,
age-related macular degeneration (AMD) is one of the most debilitating ocular conditions that can dramatically impair the quality of
life in seniors.3 It is a degenerative disease of the macula resulting in
a loss of central vision, and central scotomas.4 As the leading cause
of central vision loss worldwide for the elderly, ahead of cataracts,
glaucoma, and diabetic retinopathy, AMD affects 0.9, 4.6, and 13.1
percent of people aged 65 to 74, 75 to 84, and >84, respectively.5
There are two types of AMD: dry AMD, which is characterized by
the accumulation of yellow deposits in the macula called drusen,
and wet/neovascular AMD, which can arise from dry AMD, and is
characterized by damage to the macula due to neovascularization.3,4
While genetics may influence the development of wet AMD, current hypotheses highlight the involvement of the pro-angiogenic
UWOMJ 84:2 | Fall 2015

molecule vascular endothelial growth factor (VEGF) in this condition.3,6 Both dry and wet AMD can progress to end-stage AMD,
which presents with bilateral, irreversible macular scars and/or
large areas of degeneration of retinal pigment epithelium, which
leads to profound vision loss, increased morbidity and a decreased
quality of life.7

current treatments
Several treatment modalities are available for the management
of AMD. Ranibizumab and bevacizumab are 2 Food and Drug Administration (FDA)-approved, anti-VEGF based agents used for the
treatment of wet AMD.8 Ranibizumab is administered monthly by
intravitreal injection, and demonstrates an acceptable safety profile.9 Ranibizumab has been shown to halt the progression of wet
AMD and improve visual acuity by 3 lines on the Early Treatment
Diabetic Retinopathy Study (ETDRS) scale in 30-40% of patients.10
However, anti-VEGF agents are ineffective for bilateral, end-stage
AMD.10–12 An optical option to manage visual impairment is the usage of handheld Galilean or Keplerian telescopes. These handheld
extraocular devices are cumbersome and have a restricted field of
view, as vision depends more on head and hand movements than on
natural eye movements.11 Currently, there is no approved treatment
for bilateral, end-stage AMD in Canada.

implantable miniature telescopes
The implantable miniature telescope (IMT), approved by the
United States FDA in 2010 for individuals over the age of 65, is a
treatment for bilateral, end-stage AMD that circumvents the problems associated with extraocular visual aids.11 This intraocular prosthetic is about the size of a pea (3.6 mm diameter, 4.4 mm length).
It contains wide-angle micro-optical lenses in a Galilean telescope
design, which when combined with the cornea of the eye, acts as a
compound telescope. This effect causes retinal image enlargement
of approximately 2.2 or 2.7 times, enabling an individual to be able
to distinguish more detail from the visual field.13 The prosthetic is
surgically placed monocularly into the capsular bag after removal
of the eye’s lens, protruding 0.1 to 0.5 mm from the pupillary plane.14
The IMT provides central vision to the eye by providing magnification and redirecting light onto the healthy perimacular areas of
the retina. Coordinated use of the implanted eye for central vision
and the fellow, non-operated eye for peripheral vision improves
eyesight for patients with bilateral end-stage AMD, allowing them
the possibility of participating in both stationary and dynamic activities. After the operation, patients are administered prednisolone
acetate eyedrops for up to 3 months, along with a standardized
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course of antibiotics to facilitate recovery.14 Additionally, patients
must agree to participate in postoperative visual training with a low
vision specialist and occupational therapist to maximize their ability to perform daily activities. The rehabilitation, typically lasting
6 months to a year, involves training patients to perform tasks at
different distances and improving hand-eye coordination in both
stationary and dynamic postures. While this process is challenging, motivated patients with good psychosocial health and realistic
goals are able to gain quality of life.
The IMT is well studied, and is the only FDA-approved telescopic prosthetic for the treatment of end-stage AMD.11 One year
postimplantation, the IMT provides a 3-line or more improvement
in both distance and near best-corrected visual acuity in 53% of patients, whereas the untreated fellow/contralateral eye showed improvements in 10% of patients.13 Using patient data over a period
of 12 years, Brown et al showed that IMT implantation in patients
with bilateral, end-stage AMD resulted in a higher quality of life
gain compared to controls (fellow/contralateral eye which underwent cataract surgery), along with a cost-utility of $19 000 USD/
QALY (<$50 000 USD/QALY is considered to be very cost effective).15

limitations
While the IMT can restore vision to some extent in patients
with bilateral end-stage AMD, it cannot prevent the macula from
further deterioration and is not considered a curative treatment.16
Thus, the IMT is not indicated for patients with active choroidal
neovascular membranes.16 Another limitation of the IMT is that the
surgical procedure to implant the IMT demands immense technical expertise, and therefore carries surgical risk. There has been a
documented 20% decline in corneal health 3 months postoperatively, though damage to the cornea after this period is minimal.17
Nevertheless, excessive damage to the corneal endothelium may
necessitate a corneal transplant.17 Due to the risks of performing
this procedure, the IMT is contraindicated in individuals with prior intraocular or cornea surgery, low baseline corneal endothelium
cell density, and/or other pathologic conditions affecting the retina.16 The surgical technique used to implant the IMT, along with
the prosthetic itself, have undergone revisions to minimize the
damage that occurs to the corneal endothelium. A recent 2013 study
showed that the “next generation” telescopic prosthesis required
smaller incisions to the eye than the current prosthetic, and that the
resultant improvements in surgical technique led to less corneal endothelial damage.18 With regards to postsurgical events, the IMT is
contraindicated in patients with cognitive impairment, as this may
limit their ability to engage in the postoperative rehabilitation that
patients receiving the prosthetic are required to attend.13,16 In addition to the rehabilitation process, patients with an IMT will still
require glasses for further vision correction.16
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summary
Bilateral, end-stage AMD is primarily a disease of the elderly.
It results in both profound and irreversible visual impairment that
can limit one’s ability to engage in activities of daily living. The IMT
is a prosthetic approved by the FDA in the United States for certain patients over the age of 65 with this condition. Implanted into
the anterior compartment of the eye, the IMT provides an intricate
means of improving visual acuity and quality of life for those with
bilateral, end-stage AMD. Ongoing refinement to both the surgical
technique and the IMT itself will address concerns over the risk of
performing the implantation. While the IMT is not a cure, it is an
improvement on the existing, handheld, extraocular devices used to
manage end-stage AMD and offers some hope to people living with
this debilitating condition.
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Dr Michael Borrie is the Program Director of the South Western Ontario Regional Geriatric Program and past Chair of the Division of Geriatric Medicine. Trained in New Zealand and Canada, Dr
Borrie shared with us his experiences from 30 years of practice in
geriatric medicine and his current roles as a clinician, researcher,
administrator, and teacher.
UWOMJ: Tell us a little about yourself.
Michael Borrie: I did a degree in biochemistry before entering
the 5-year medical school training in New Zealand. After medical
school, we do 2 years as a “house surgeon”, after which we could
practice family medicine. I wished to pursue internal medicine and
trained in Edmonton, Alberta and then London, Ontario to specialize in geriatric medicine. I met my spouse, Nancy, in my 4th year in
London. We moved to Dunedin, New Zealand where I did 2 years as
a research fellow and where we had the first of our three daughters.
We returned to London in 1985. It was very busy doing mainly clinical service on a 40-bed geriatric rehab unit and I was also one of the
attending physicians on general internal medicine, doing 1-in-3 call.
What is special about geriatrics?
I enjoyed internal medicine. Yet, during the subspecialty rotations, I was looking at the patient through the lens of a single organ system. After stabilizing a heart failure for an elderly patient,
we were then asked about their arthritis, which we never had the
opportunity to address. This was not my idea of patient-centred
medicine and not fully satisfying. This confirmed that I wanted to
manage older people, multi-system disease and the related complexities, and the field of geriatric medicine was clearly for me.
Geriatric medicine is special because you can analyze an event
such as a fall and split out the multiple factors. Often, 6 or more
different factors combine to cause a person to eventually fall. That
is the nature of geriatrics. You have a single syndrome: falls, confusion, incontinence or polypharmacy. You can dissect it out and ask
“what are all the reversible and irreversible factors” and then focus
on the reversible elements.
What do you like most about being a geriatrician?
It’s a very satisfying career. Older patients are very appreciative
of what you do and they’re very respectful. They don’t always follow advice but that’s no different than other patients. I can’t change
the world but I can do multiple small things for their many complex
diseases to make a difference to their quality of life and, ultimately, this is what medicine comes down to—improving the quality of
someone’s life.
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Geriatric medicine deals with multiple chronic diseases and
their complex interaction. I enjoy the intellectual stimulation of
understanding a person’s history, as well as the clinical examination and investigations. I have the luxury of time for a full history,
examination, and comprehensive counselling that may make a difference.
Research has always interested me. There are many research
opportunities in geriatric medicine from the basic science of individual diseases, to clinical trials of novel compounds, to knowledge
translation that changes patterns of clinical practice and mindful
clinical care.
Our division is one of the largest and well-integrated divisions
across the country. We can support some of us to lead as clinical
educators or clinician-scientists and everything in between. Each of
the geriatricians pursues his or her individual strengths and works
together with allied health professional teams to exemplify best
practices, care, and education for older adults in our region.
What are your current responsibilities?
I do approximately equal amounts of research, administrative
work, and clinical work, as well as clinical teaching in the outpatient clinic or on the geriatric rehabilitation unit.
In 1985, I began my career as a geriatrician and by 1995, became the chair of the division. I was one of 4 geriatricians and over
the next 15 years took on the leadership and administrative role of
the division. We recruited geriatricians and built the division to 11
members. As an academic geriatrician, you can develop as a clinician, researcher or clinician-teacher, although it should be noted
that it is difficult to do both clinic work and research.
Through my training, interests and opportunities in Canada, I
have evolved as a clinician-researcher. My research focus was initially on Alzheimer disease and also on urinary incontinence. In the
early 1990s, we began new trials in Alzheimer disease and offered
participation in these clinical trials to patients seen in the Aging
Brain and Memory Clinic. Over the last 10 years, the focus has been
on treatments for the amyloid hypothesis and disease modification.
The trials are more complex lasting several years and require positron emission tomography imaging for amyloid.
Can you outline the 2+1 Care of the Elderly option vs 5-year
training in Geriatric Medicine?
Family physicians with an extra year in Care of the Elderly can
be very effective physicians in geriatric care. The longer they practice in geriatric care, the more the distinction between their clinical
practice and that of a geriatrician narrows.
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profiles
Care of the Elderly-trained physicians who pursue an academic career are more likely to have an academic role as educators rather than researchers, unless they have additional research training.
In community practice they may be the physician lead providing
consultation or direct management for the elderly patients within a family health team. They may pursue the Care of the Elderly
training to develop additional skills for the management of elderly
patients within their practice.
As you complete your medical degree, if you are unsure if you
want a career in family medicine with geriatrics as a focus or a career in geriatric medicine, entering an internal medicine program is
always a good idea. It is easier to switch into family medicine from
internal medicine than the reverse, and you will be a better physician for having done additional training in internal medicine.
In Ontario, of the 130 geriatricians who have completed the
subspecialty 5-year training in geriatric medicine, half are in academic centres and half are in community settings.
What are the opportunities and challenges in the future for geriatrics?
My bias is towards the opportunity to prevent, manage and
treat cognitive impairment. Cognitive impairment is the one condition that threatens a person’s independence. Right now the direct
and indirect costs due to cognitive impairment/dementia are about
$10 billion a year. By 2038, the costs are estimated to be $150 billion
per year. The biggest driver of direct costs is people with cognitive
impairment staying in acute care beds and eventually having to live
in long term care institutions. We could do so much more to prevent
cognitive decline and its progression.
Historically, acute care hospitals were built to treat acute illnesses. We can do much better at preventing delirium following
surgery or medical interventions. There is an irreversible component of delirium and patients will deteriorate during an acute care
admission. This will result in longer hospital stay and drive up our
health care costs.
The challenge to future physicians will be developing smarter
models of care. Technology will affect health care and you will have
very tech-savvy elderly patients in your practice. For example, as a
consultant, communication will include e-consults and there will
need to be different funding models to support this.
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What are your hobbies or personal interests?
My wife and I love to regularly do social and Latin dancing.
We’ve been doing this since 2005. It’s good for our brain and our
relationship. I’ve always enjoyed swimming—in high school as a
competitive swimmer—and now recreationally whenever I have
the opportunity.
Any advice for medical students interested in geriatrics?
Take advantage of any opportunities for clinical rotations and
exposure to geriatric medicine during your training. Get research
experience in geriatrics, such as the summer research training program.
Do you have any thoughts about the recent ruling in favour of
legalizing physician-assisted suicide (PAS)?
In 30 years of practice, I cannot think of a patient encounter
where I’ve said that the only option at this point is assisted suicide.
That may mean that people who would benefit from PAS have never come to a geriatrician. There may well be a few people for whom
assisted suicide might be the only option. However, I think one has
to be cautious about assisted suicide and the potential for a slippery
slope. If it is thought through very carefully and there are appropriate policies and safeguards in place, there may be some people who
could benefit. Most people with severe pain are managed appropriately and assisted suicide does not have to be considered. As a
society, we need to protect people who are vulnerable, particularly
older individuals with disabilities or cognitive impairment, so that
they don’t feel they have to “move on” and do the honourable thing.
Fortunately for me, in geriatric medicine, I have never felt the need
to consider this option. I work with teams and when appropriate
we aim to provide the best end-of-life care.
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Anticholinergic toxicity, polypharmacy,
and inappropriate prescribing
Nicole Arseneau (Meds 2018), Kevin Braden (Meds 2017)
Faculty Reviewer: Dr Jennie L Wells, BSc, MSc, MD, FRCPC, FACP (Division of Geriatric Medicine)
An 84-year-old woman, Doris, is brought to the ER by her
daughter just after 2300 on a Tuesday night, complaining of a racing heart beat and palpitations. She is agitated and very uncooperative. Her daughter is worried about how strange Doris is acting.
She mentions that the patient had an myocardial infarction (MI) 5
years ago, is diabetic, and takes a number of medications before bed
at about 2130.
Adults over the age of 65, like Doris, are more likely to visit an
emergency department than younger individuals.1,2 In addition,
older adults tend to have more comorbidities, take more medications (polypharmacy), have higher rates of dementia and other
neuropsychiatric disorders, and may present with unconventional
and nonspecific symptoms.2-5 Unsurprisingly, physicians without
specialized geriatric training report feeling less confident when
treating older patients in the emergency department compared to
younger patients.2
Doris is becoming increasingly agitated and confused. On
examination, her skin appears erythematous, hot, and dry to the
touch. Her oral temperature is 37.8˚C. She has slight bilateral mydriasis. Her respiratory rate is slightly rapid at 20 breaths per minute,
her oxygen saturation is 99%, and there is no obstruction of her airway. With some effort, an electrocardiogram is obtained showing
sinus tachycardia at 116 beats per minute and her blood pressure is
slightly elevated at 140/85 mmHg. A fingerstick glucose test shows
that her blood glucose is 5.8 mmol/L, within normal limits.

anticholinergic toxicity
Doris’ attending physician suspects that she is suffering from
anticholinergic toxicity due to her classic constellation of symptoms. An anticholinergic toxidrome may present when a medication or poison antagonizes muscarinic receptors throughout
the body causing a variety of potentially dangerous effects, often
remembered by the mnemonic “hot as a hare (hyperthermia), dry
as a bone (anhidrosis), red as a beet (vasodilation), blind as a bat
(mydriasis), mad as a hatter (delirium and hallucinations), and full
as a flask (urinary retention).”6 Anticholinergic effects are more
prevalent in the elderly population, in part due to age-related pharmacokinetic and pharmacodynamic changes.7-9 Specifically, changes in body composition, including a higher percentage of fat, can
increase a drug’s volume of distribution and impair elimination of
certain drugs, including anticholinergics. Furthermore, a drug’s
half-life may be significantly prolonged in elderly patients due to
liver or kidney impairment.10 As such, the American Geriatrics Society recommends that most anticholinergic medications should be
avoided in older adults.8 Anticholinergic toxicity may result from
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intentional or unintentional poisoning, overdose, and medical oversight.6,8,12 In Doris’ case, it is likely that one or more of her medications is causing this acute reaction, though which drug remains
unknown.
Doris is moved into an isolated psychiatric care room in the
emergency department with her daughter, and her agitation lessens
thereafter. Her symptoms do not appear to be life threatening, and
have not worsened since her admission. Complete blood count,
electrolytes, and arterial blood gases are normal. She continues to
be monitored closely.
Treatment of a patient with anticholinergic toxicity varies
based on symptoms, time since the exposure, route of administration, patient delirium and aggression, as well as other patient
factors. Many cases, such as Doris’, can be treated supportively.
Activated charcoal can be given to decontaminate the gastric compartment if the suspected agent was given orally. It is most effective
if the instigating drug is known to bind to charcoal and was ingested within the last hour. In Doris’ case, the drug is unknown and
ingestion was most likely over an hour ago. The physician also does
not want to interfere with the absorption of her other medications.
Physostigmine can be given as an antidote to certain anticholinergic agents in the event of a poisoning; however, it has a number of
potential adverse reactions including seizures, bradycardia, heart
block, and bronchospasm.13-15 Doris’ physician is hesitant to start
any potentially dangerous treatments when her condition appears
to have stabilized.

prescribing cascade
Doris remains overnight in the emergency department for
observation. In the morning, her vitals have partially normalized
and she is no longer agitated. She is able to give a complete history,
which is significant for an MI 5 years ago, hypertension, seasonal
depression, type II diabetes mellitus, and osteoporosis. She is currently taking 13 daily medications for these conditions: propranolol, captopril, low dose ASA, hydrochlorothiazide, metoclopramide,
fluoxetine, amitriptyline, rosuvastatin, metformin, naproxen, ranitidine, alendronate, and a calcium/vitamin D supplement. She has
also been taking an over the counter (OTC) cold remedy for a persistent cough. She often feels tired during the day and drinks plenty
of coffee to stay awake. Recently she has had some trouble falling
asleep. On her daughter’s advice, she took two diphenhydramine
tablets as a sleep aid.
Doris’ list of medications is concerning both for its contents
as well as its length. Many of her medications are clearly aimed at
managing her current conditions; for example, alendronate and her
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calcium/vitamin D supplement are most likely related to her osteoporosis. However, it is possible that some of her medications are
simply treating side effects of other medications. This is referred to
as a prescribing cascade. Prescribing cascades are common in the
elderly population, particularly when the patient is not educated
about the potential side effects of a new medication. For example,
a persistent cough that Doris is treating with an OTC cold remedy
is a common side effect of acetylcholinesterase (ACE) inhibitors
such as captopril. Another well known prescribing cascade is the
use of metoclopramide to treat nausea associated with any number
of drugs.5,16 Furthermore, Doris’ fatigue may be due to her cardiac
medications (most likely propranolol), which may influence her
coffee consumption, which in turn could have necessitated her use
of diphenhydramine as a sleep aid. The combination of diphenhydramine, an anticholinergic sedating H1 antihistamine, with an
OTC cold remedy (likely containing other anticholinergic medications, such as chlorpheniramine and dextromethorphan) is the
most likely cause for her hospitalization.8,10,13 It is recommended
that diphenhydramine use be restricted in all patients of advanced
age, except for treatment of severe acute allergic reactions.8 While
diphenhydramine administration appears to be the precipitating
factor for Doris’ condition, some of her other medications also have
anticholinergic effects, notably amitriptyline and ranitidine.8,11–13
Once Doris’ symptoms have resolved, she is discharged home
with the recommendation that she follow up with her family doctor. She is instructed not to take any more diphenhydramine or OTC
cold remedy.

some improvements to be made. The physician suggests replacing
captopril, an ACE inhibitor, with an angiotensin II receptor blocker
such as losartan. This may relieve Doris’ cough while still reducing
her blood pressure. In addition, switching from thrice-daily captopril to once-daily losartan may be beneficial as dosing frequency
is inversely related to medication compliance.19 The physician also
suggests that naproxen be replaced with acetaminophen for pain
control to reduce the risk of salt retention, hypertension, and GI
bleeds.8,11 It is recommended that Doris’ depression be managed by
citalopram instead of her current antidepressants, as amitriptyline
is an anticholinergic agent, and fluoxetine is associated with both
anorexia and numerous cytochrome P450 interactions.6,8 Finally, it
is recommended that both ranitidine and metoclopramide be discontinued, as both have anticholinergic properties, and metoclopramide in particular is known to precipitate extrapyramidal and parkinsonian symptoms in the elderly. These reductions and changes
in Doris’ medications should reduce her overall anticholinergic
burden as well as her risk for adverse drug events and interactions.
Polypharmacy, inappropriate prescribing, and adverse drug
reactions are an exceedingly common yet preventable source of illness, hospitalization, morbidity, and mortality in the elderly population, yet these undesirable outcomes are also preventable in many
cases.9,18 It is vitally important for physicians to be mindful of these
issues. Physicians should review the indications and contraindications for all medications as well as educate their patients on side
effects of both OTC and prescription medications.

polypharmacy and inappropriate prescribing

1.

Doris’ case highlights the dangers of polypharmacy, often defined as using more than 5 drugs routinely.9,12,17 Polypharmacy is
increasingly prevalent in the elderly population, with more than
25% of Canadian adults over the age of 65 taking more than 5 medications daily.9 Polypharmacy is believed to be due, at least in part,
to more comorbidities in this age range as well as prescribing cascades, as described above.2,9,12,16 People taking more medications,
especially the elderly, are at increased risk for adverse drug reactions, which are a significant cause of hospitalization, morbidity,
and mortality.9,10,18 Up to 25% of older adults report experiencing an
adverse drug event within the past year, some requiring hospitalization.9,18 Notably, many older adults are taking OTC, herbal, and
dietary preparations in addition to prescription medications, which
may contribute to drug interactions and side effects,5 as in Doris’
case. Nevertheless, polypharmacy itself is not necessarily harmful.
Patients may be on several medications, all of which are appropriate for their conditions.11,12 What is more concerning in this population is the higher potential for inappropriate prescribing, most
likely due to the complexity of medication use.12 There are several
tools available to physicians to evaluate the appropriateness of a
medication in the elderly population, including the Beers Criteria
and STOPP Criteria.8,11,12 However, even with these tools in place,
up to 40% of nursing home residents in one study were prescribed
at least one inappropriate medication.12,17
Doris’ family physician notes that several of Doris’ medications
are being used appropriately to treat her conditions, but there are
UWOMJ 84:2 | Fall 2015
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Rare cancer, common conversation

A case of T-cell prolymphocytic leukemia with end-of-life discussions
Craig Olmstead (Meds 2017), Charles Jian (Meds 2018)
Faculty Reviewer: Dr Cyrus Hsia, MD, FRCPC (Division of Hematology)

introduction
Cancer in its many forms is particularly common in elderly populations. For females over the age of 80 in Canada, approximately
2% will have a new diagnosis of cancer each year.1 With thousands
of types and subtypes, cancer is a heterogeneous spectrum of diseases, each with its own difficulties in establishing a diagnosis and
an effective management strategy.
The diagnosis and treatment of cancer in the elderly is fraught
with additional challenges. Symptoms in the elderly may be atypical or less pronounced compared to younger patients. Seniors
often have multiple pre-existing conditions and comorbidities in
addition to their presenting complaint. Most geriatric patients take
numerous medications, complicating a straightforward diagnosis
and confounding a simple treatment plan.2-4 Cognitive impairment,
whether due to pathology or physiological decline, can be a complicating factor, hampering physician-patient interactions.2 Even good
clinicians can still struggle with the complexities of common malignancies in an elderly patient due to these additional factors. Rarer
malignancies can be that much more challenging.
Here, we present a case of a patient diagnosed with an exceptionally rare hematologic cancer in combination to other comorbidities, and explore how the health care team and the family was
able to collaborate to develop a treatment plan acceptable to both
parties.

On physical examination CB did not appear ill. However, the
exam revealed positive bilateral lymphadenopathy in the neck, axilla, and inguinal regions. Fine inspiratory crackles were noted in
the left lower base of the lung. Tender splenomegaly, palpable down
to the left lower quadrant, was also found. No hepatomegaly was
noted.5
After being admitted to hospital, computed tomography revealed an enlarged spleen occupying two-thirds of the left abdominal cavity, a small pleural effusion at the left lung base, and enlarged
lymph nodes along the gastro-hepatic ligament, the porta hepatis,
the mesentery, and both groins. Complete blood count was remarkable for a white blood cell count exceeding 70 000 with atypical
lymphocytes and 20% blasts. Platelets were low at 60 000. A referral to hematology/oncology was made to investigate possible lymphoma or leukemia. Peripheral smears revealed lymphocytes with
nuclear contour irregularities, cytoplasmic border irregularities,
and rare nuclear clefts. Prominent nucleoli were lacking in most
cells. Bone marrow biopsy revealed significantly increased hypercellularity consisting primarily of small lymphocytes. Flow cytometry detected aberrant CD4+/CD8¬ T-cells and was positive for
clonal rearrangement of the TCR-β gene, suggesting T-cell leukemia. CB was negative for human T-cell lymphotropic virus-1, ruling
out adult T-cell lymphocytic leukemia. A final diagnosis of T-cell
prolymphocytic leukemia (T-PLL) was made.5

initial presentation and diagnosis

t-cell prolymphocytic leukemia

The patient, CB, was an 83-year-old female retired hairdresser
who presented with her daughter to her primary care provider with
a 1-2 month history of left upper quadrant pain. Initially, CB’s pain
was ill-defined, intermittent, and did not limit her activities, but
worsened significantly over the few days before the visit.5
On presentation, CB was holding her left side and grimacing in
pain. CB had an extensive past medical history headlined by mild
vascular dementia and heart block requiring a pacemaker. She also
had a history of hypertension, hyperlipidemia, bilateral carotid stenosis, and scoliosis. CB’s medications included aspirin 81 mg daily,
metoprolol 100 mg twice daily, verapamil 240 mg daily, donepezil
10 mg daily, ezetimibe 10 mg daily, fluvastatin XL 80 mg daily, and
memantine 10 mg twice daily. CB’s adult children who lived nearby
provided assistance with medications and meals during daily visits,
resulting in good compliance to her prescriptions and reasonable
nutrition status. CB also retained many of her activities of daily living despite her conditions; she dressed, bathed, toileted, and ambulated without assistance. CB was a nonsmoker and consumed 3-4
beers per day. Despite her dementia CB had some ability to make
decisions regarding her life and health, relying on her daughter
more in an advisory capacity on matters needing clarification.5

T-PLL is a rare malignancy, typically affecting those 65 or older, with males somewhat more affected than females. Previously
described as a variant of chronic lymphocytic leukemia (CLL), it
represents less than 1% of all mature lymphocytic leukemia diagnoses.5,6 While most forms of PLL are malignancies of B-cells, T-PLL
is a malignancy of mature T-cells. It is a particularly aggressive form
of lymphocytic leukemia, with reported median survival times after
diagnosis counted in months.7
As T-PLL is quite rare, diagnosis can be difficult. A key feature
of T-PLL is dramatic splenomegaly, palpable 10 cm below the left
costal margin in over 80% of patients. Other potential symptoms
include hepatomegaly, ascites, lymphadenopathy, lymphocytosis,
pleural effusions, skin lesions, and CNS involvement.6 Further testing typically involves peripheral smears and bone marrow biopsies.
Immunophenotype features of T-PLL include the presence of CD52
as well as T-cell markers CD2, CD3, and CD7.7 Genetic features include clonal rearrangement of TCR genes.8
Typical cancer treatments such as splenectomy, splenic irradiation, leukaphoresis, or standard chemotherapy are largely ineffective. The primary therapy is a monoclonal antibody called alemtuzumab, which targets CD52 and was created to treat B-cell CLL
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resistant to standard chemotherapy. CD52 targeting causes cancer
cell lysis by apoptosis through a host effector mechanism. Trials
have shown remission rates of up to 30 months in patients with
T-PLL, and several further studies found a median survival time of
14.8 months with treatment. Hematopoietic stem cell transplantation is an option for those who achieve complete remission with
alemtuzumab. Alemtuzumab is associated with serious toxicities,
particularly myelosuppression. Potential adverse effects include
severe infections, bleeding crises, and hypersensitivity reactions.
Regrettably, in all cases the cancer eventually relapses.7,9,10

treatment and follow-up
The health care team engaged in a detailed discussion with
CB and her family regarding beliefs, quality of life, and the options
available for palliative and curative treatment. Given CB’s advanced
age and multiple comorbidities, the likelihood of a negative outcome from toxicities or side effects was significant. Officially, CB’s
daughter was the surrogate decision maker. However, she wanted
CB to be given the opportunity to choose her own treatment, despite the possibility that she may not be fully aware of the risks and
benefits of treatment. Ultimately, CB opted for chemotherapy with
alemtuzumab, stating that she “just wasn’t ready to die yet.” A modified treatment regimen with subcutaneous injections and a slow
introduction of alemtuzumab was initiated to minimize the potential for side effects.5
Cost was another challenge faced by the health care team. A 12week course of alemtuzumab costs over $240 000. The oncologist
and CB’s daughter collaborated closely to find outside sources of
funding to help cover this cost. An infusion center was found several days later, and chemotherapy was initiated in a timely manner.5
CB tolerated the treatment well, with few side effects. After 6
weeks of therapy there was a significant reduction in splenomegaly
and lymphadenopathy, with the white blood cell (WBC) count returning to 2.2, and platelets returning to 176 000. Following the 12week treatment CB was discharged on antibiotics as a result of T-cell
obliteration and followed monthly. At two months post-treatment,
she was still asymptomatic, with a WBC count of 6.7 and platelets at
143 000. At three months post-treatment her T-cell counts returned
to 200 000 and antibiotic therapy was discontinued.5
CB continued to live in her own home post-therapy. She celebrated her 84th birthday with family and friends, and was able
to travel to her hometown to visit her remaining family members.
However, 4 months post-therapy she began to develop recurring
left upper quadrant pain and splenomegaly. Palliative radiation
therapy was offered. CB’s daughter, after discussion with the rest
of the family, refused radiation therapy and other treatment options
on grounds that it would not bring CB an acceptable quality of life.
CB was kept in her home with hospice care for pain management
and end-of-life care. Despite her deteriorating condition, she remained mobile and active until 3 days prior to entering a comatose
state. She died shortly thereafter with her family at her bedside.5
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discussion
The medical side of this case involves an exceedingly rare, but
notably aggressive form of leukemia. Establishing a diagnosis of
T-PLL can be troublesome given its rarity and its nonspecific symptoms on presentation. Treatment is frequently minimally effective,
with the main prognostic factor being response to alemtuzumab.7
As T-PLL is primarily a disease of the elderly, both diagnosis and
treatment can be challenging. In this case, dementia proved to be
the main hurdle, as concerns of comprehension by CB were noted by the involved clinicians.5 Nevertheless, physicians should be
aware of this rather unique form of hematologic malignancy, mindful of its defining features on physical exam and be prepared to
make appropriate referrals to hematology/oncology when suspicion of T-PLL is high.7
However, at its core this case is worth highlighting for the manner in which end-of-life discussions occurred. In an aging society,
the strategies for addressing terminal illness in the context of cognitive decline become increasingly important.2,4 This case underlines
the necessity of including all key stakeholders in the conversation
about treatment options, including clinicians, patients, and family
members.2,5 Not every malady is curable, but all patients can feel
cared for by their medical team.
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